Envafolimab
- Generic Name
- Envafolimab
- Drug Type
- Biotech
- CAS Number
- 2102192-68-5
- Unique Ingredient Identifier
- ES1M06M6QH
- Indication
用于不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复基因缺陷型（dMMR）的成人晚期实体瘤患者的治疗，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
Phase 2
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 590
- Registration Number
- NCT06959693
- Locations
- 🇨🇳
Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Target Recruit Count
- 40
- Registration Number
- NCT06791083
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, FuZhou, Fujian, China
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT06734182
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Phase 2
Not yet recruiting
- Conditions
- Rare Tumour
- Interventions
- Drug: Other
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Phase 1
Recruiting
- Conditions
- Prostate CancerCDK12 Gene Mutation
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT06663007
- Locations
- 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Unresectable Biliary Tract Carcinoma
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 30
- Registration Number
- NCT06656559
D-TACE-HAIC Combined With Envafolimab and Lenvatinib in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: a Prospective, Single-arm, Phase II Clinical Study
Recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06643208
- Locations
- 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
Local Injection and Systemic Therapy in the Treatment of NSCLC.
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT06618391
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Phase 2
Recruiting
- Conditions
- MSSRAS MutationMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Beijing Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06321081
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
Phase 2
Recruiting
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 16
- Registration Number
- NCT06301828
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath